Geode Capital Management LLC Purchases 259,010 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Geode Capital Management LLC boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 10.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,700,782 shares of the company’s stock after acquiring an additional 259,010 shares during the period. Geode Capital Management LLC’s holdings in Vaxcyte were worth $308,675,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Envestnet Portfolio Solutions Inc. bought a new stake in shares of Vaxcyte during the second quarter worth $202,000. Assenagon Asset Management S.A. acquired a new position in Vaxcyte in the 2nd quarter worth $213,000. Sumitomo Mitsui Trust Holdings Inc. bought a new position in Vaxcyte during the 2nd quarter worth about $342,000. Raymond James & Associates raised its stake in shares of Vaxcyte by 4.7% in the 2nd quarter. Raymond James & Associates now owns 69,437 shares of the company’s stock valued at $5,243,000 after purchasing an additional 3,105 shares during the period. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Vaxcyte by 64.8% in the second quarter. Nisa Investment Advisors LLC now owns 2,099 shares of the company’s stock valued at $158,000 after purchasing an additional 825 shares in the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 42,000 shares of the company’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $115.39, for a total value of $4,846,380.00. Following the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,429,294.37. The trade was a 31.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mikhail Eydelman sold 5,000 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $109.27, for a total transaction of $546,350.00. Following the sale, the senior vice president now owns 28,623 shares of the company’s stock, valued at approximately $3,127,635.21. This represents a 14.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 117,830 shares of company stock worth $12,600,310 over the last 90 days. Company insiders own 3.10% of the company’s stock.

Vaxcyte Trading Down 0.2 %

NASDAQ PCVX opened at $87.72 on Friday. The firm has a market capitalization of $10.93 billion, a P/E ratio of -19.07 and a beta of 0.94. The firm’s fifty day moving average price is $101.11 and its two-hundred day moving average price is $91.68. Vaxcyte, Inc. has a 1 year low of $53.83 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the business earned ($0.91) EPS. On average, research analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on PCVX. Mizuho increased their price objective on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Jefferies Financial Group boosted their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. BTIG Research raised their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, Bank of America boosted their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte currently has an average rating of “Buy” and an average price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.